Will Late Loss Debate Stifle Device Start-Up Innovation?

The failure of Medtronic's Endeavor stent to hit its primary clinical trial endpoint has again spurred debate over surrogate endpoints, a potentially big issue for small companies.

More from Clinical Trials

More from R&D